Exchange: TSX·Updated 04:00 PM EDT
About CPH.TSX
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. It acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products. Its pipeline includes Nail Fungus (MOB-015), Moderate to severe plaque psoriasis (CF-101), and Tattoo removal (DTR-001). The company was founded on January 9, 2004 and is headquartered in Mississauga, Canada.